Ingress end-point validation studies can help you in your discussions with local health authorities
The Ingress team can help you select and conduct end point validation studies. The choice of surrogate and true end points has become a critical issue and one that is currently the subject of much debate. The question of whether an end point can be considered an acceptable surrogate endpoint depends not only on formal validation studies but also on a standardized definition and unbiased ascertainment of disease progression in clinical trials. For reimbursement purposes it is important to validate a surrogate endpoint to ensure it is accepted by the relevant health authorities. Besides trial data, health authorities also find it increasingly important to validate end-points based on real world evidence.
By completing your details below you are agreeing to receive communications and updates from us including but not limited to news, the latest publications, and invitations to Ingress-Health company events.